根據衛福部國健署調查顯示，台灣脂肪肝盛行率高達33%1
這意味著每3人中就有1人面臨脂肪肝威脅。你也是其中的一員嗎？
認識脂肪肝
Q1
脂肪肝會變成肝癌嗎？別被「無症狀」騙了！脂肪肝就是肝在生病
脂肪肝大多無明顯症狀，讓許多人輕忽它帶來的潛在風險，可能在沈默中逐步演變為慢性肝病、肝硬化，甚至是肝癌。... 閱讀更多
脂肪肝
脂肪堆積肝臟引起輕度發炎，或肝細胞受損(此階段仍可逆)
代謝異常脂肪肝炎
脂肪肝未治療，惡化成為代謝異常脂肪肝炎(此階段仍可逆)
肝纖維化
肝臟慢性受損後形成疤痕組織
肝硬化
肝臟纖維組織形成結節狀，導致肝臟表面凹凸不平，質地變硬
肝癌
肝臟內細胞突變後，不停分裂形成腫瘤，並侵占周邊健康組織
認識脂肪肝
Q2
脂肪肝的風險有哪些？放任肝生病，後果真要命！
許多研究已證實，不只肝癌，脂肪肝與心血管疾病、糖尿病5、甚至失智症風險6皆有關連。... 閱讀更多
心血管頭號威脅
代謝異常脂肪肝炎會引發全身性慢性發炎，研究顯示70%脂肪肝炎患者死於心血管相關疾病7。
肝癌距離你很近
近50%代謝異常脂肪肝炎患者惡化為肝癌，且腫瘤體積通常更大、進程更猛烈8。
多數確診即晚期
約40-52%代謝異常脂肪肝炎患者，確診時肝臟已處於中度或重度纖維化9。
認識脂肪肝
;%20}%20}%20@keyframes%20shake%20{%200%25,%20100%25%20{%20transform:%20rotate(0deg);%20}%2025%25%20{%20transform:%20rotate(-6deg);%20}%2075%25%20{%20transform:%20rotate(2deg);%20}%20}%20.spin%20{%20transform-box:%20fill-box;%20transform-origin:%20center%20center;%20animation:%20spin%208s%20linear%20infinite;%20}%20.shake{%20display:%20inline-block;%20transform-box:%20fill-box;%20transform-origin:%20center%20center;%20animation:%20shake%202s%20ease-in-out%20infinite%20alternate;%20}%20%3c/style%3e%3c/defs%3e%3cg%20id='_圖層_1-2'%20data-name='圖層%201'%3e%3cg%3e%3cg%20class='shake'%3e%3cpath%20class='cls-1'%20d='M111.08,44.43l-33.32,33.32-36.81-36.81L74.27,7.62c10.16-10.16,26.64-10.16,36.8,0,10.17,10.17,10.17,26.65,0,36.81Z'/%3e%3cpath%20class='cls-3'%20d='M77.75,77.75l-33.32,33.32c-10.17,10.17-26.65,10.17-36.82,0C2.54,105.99,0,99.33,0,92.67,0,86.01,2.54,79.35,7.62,74.26l33.32-33.32,36.81,36.81Z'/%3e%3cpath%20class='cls-2'%20d='M40.94,40.95L7.62,74.26C2.54,79.35,0,86.01,0,92.67c0,6.66,2.54,13.32,7.62,18.4,5.08,5.08,11.75,7.63,18.41,7.63s13.32-2.54,18.41-7.63l33.32-33.32-36.81-36.81ZM41.78,108.42c-4.21,4.21-9.81,6.53-15.76,6.53s-11.55-2.32-15.76-6.53c-4.21-4.21-6.53-9.8-6.52-15.75,0-5.95,2.32-11.55,6.53-15.76l30.67-30.67,31.51,31.51-30.67,30.67Z'/%3e%3c/g%3e%3cg%20class='spin'%3e%3cpath%20class='cls-3'%20d='M121.54,128.15c-9.22,6.15-21.79,5.16-29.93-2.97s-9.13-20.71-2.97-29.93l32.9,32.9Z'/%3e%3cpath%20class='cls-3'%20d='M128.15,121.55l-32.9-32.9c9.22-6.16,21.79-5.16,29.93,2.97,8.13,8.14,9.13,20.71,2.97,29.93Z'/%3e%3cpath%20class='cls-1'%20d='M128.15,121.55s-.05.08-.08.12c-.83,1.24-1.8,2.41-2.89,3.51s-2.27,2.06-3.5,2.89c-.04.03-.08.06-.13.08l-32.9-32.9s.05-.08.08-.12c.83-1.24,1.8-2.41,2.89-3.51,1.09-1.09,2.27-2.06,3.5-2.89.04-.03.08-.06.13-.08l32.9,32.9Z'/%3e%3cpath%20class='cls-2'%20d='M125.17,91.62c-4.63-4.63-10.7-6.95-16.77-6.95v3.75c5.33,0,10.35,2.08,14.12,5.85,6.76,6.76,7.79,17.4,2.43,25.31-.71,1.05-1.53,2.04-2.43,2.95-.91.91-1.9,1.72-2.96,2.44-3.3,2.23-7.17,3.42-11.18,3.42-5.34,0-10.35-2.08-14.13-5.85-6.76-6.76-7.79-17.4-2.43-25.31.71-1.05,1.53-2.04,2.43-2.95.91-.91,1.9-1.72,2.96-2.44,3.3-2.23,7.17-3.41,11.18-3.42v-3.75s0,0,0,0c-4.64,0-9.28,1.35-13.28,4.06-1.24.83-2.41,1.8-3.5,2.89-1.09,1.09-2.06,2.27-2.89,3.5-6.25,9.23-5.28,21.88,2.89,30.05,4.63,4.63,10.7,6.95,16.78,6.95,4.64,0,9.28-1.35,13.28-4.06,1.23-.83,2.41-1.8,3.5-2.89,1.09-1.09,2.06-2.27,2.89-3.5,6.25-9.23,5.28-21.88-2.89-30.05Z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Q3
有脂肪肝怎麼辦？專業醫療介入，逆轉脂肪肝！
脂肪肝治療已從單純的生活型態調整，邁入醫學突破的新里程。過去治療糖尿病或抗氧化的藥物展現輔助效果，目前更發展出專屬藥物，協助有效管理代謝指標，降低肝病變的風險。
項目
Semaglutide
Silymarin
Tirzepatide
成份
GLP-1 腸泌素
水飛薊素
GIP及GLP-1
主要用途
- 治療脂肪肝炎
- 治療第二型糖尿病
- 體重管理
- 心血管保護
- 慢性肝病的營養補給品
- 脂肪肝輔助治療
- 體重管理
- 治療第二型糖尿病
預期脂肪肝治療效果
- 降低肝臟脂肪
- 降低肝指數(AST/ALT)
- 脂肪肝炎緩解
- 肝纖維化改善
- 降低肝指數(AST/ALT)
無
有效時間
7天
6小時
5天
閱讀更多
脂肪肝就是肝在生病！它也是心血管疾病與器官受損的預警，挽回彩色人生，快給醫生看，逆轉脂肪肝！
肝健康風險
你也是脂肪肝代謝危機「候選人」嗎？快來評估脂肪肝風險有多少！
脂肪肝紅黃綠行動分級10
從脂肪肝到代謝異常脂肪肝炎、纖維化是一條漸進但可逆之路，只要我們及早發現、及早行動，就能逆轉這全身性的代謝危機。
自我評估脂肪肝風險
外表看起來瘦，就代表肝臟健康嗎？
1分鐘，測量你的肝臟壓力指數
綠燈
黃燈
紅燈
外表可能騙了你，內臟脂肪正在悄悄囤積。
建議諮詢醫師進行精準檢測，
別讓輕度脂肪肝演變成脂肪肝炎。
分 級
綠燈
無脂肪肝
維持健康，預防發生
定期健康檢查
- 40歲以下：每2到3年定期健檢一次
- 40歲以上：每年一次定期健檢
- 均衡飲食（少油、少糖、少精緻澱粉）
維持健康生活型態
- 每週至少150分鐘中等強度有氧運動（如快走）或75分鐘高強度運動（如跑步）、至少2次肌力訓練
- 腰圍維持標準（男<90cm、女<80cm）
- BMI 建議 <23
健康小叮嚀
沒有脂肪肝，
不代表沒有代謝風險
診所地圖
別讓沈默的脂肪肝，偷走你的彩色人生！
脂肪肝絕非「不痛不癢」的小毛病，而是肝有病！立即搜尋鄰近診所，預約專業諮詢，逆轉脂肪肝！
資料來源:
- 衛生福利部國民健康署。（以台灣約 2,000 萬成年人口計算，受影響人數約為 670萬人。）
- Israelsen, M., et al. (2024). "Steatotic liver disease." The Lancet, 404(10464), 1761-1778.
- J Hepatol . 2024 Feb;80(2):e76-e77. doi: 10.1016/j.jhep.2023.08.026.
- Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study
- Targher, G., et al. (2020). "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis." The Lancet Gastroenterology & Hepatology.
- Shang, Y., et al. (2022). "Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study." Neurology
- nengl j med 393;7 nejm.org August 14, 2025; Schattenberg JM et al. Presented at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)2024, December 12–14 2024, Los Angeles, California.
Younossi ZM, et al. (2016). "Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. - NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
- Harrison, S. A., et al. (2023). "Prospective evaluation of the natural history of non-alcoholic fatty liver disease (NAFLD)." The Lancet Gastroenterology & Hepatology.
- AASLD Practice Guidance(2023)Rinella ME, et al. AASLD Practice Guidance on NAFLD/MASLD. Hepatology. 2023.
TW26SN00018 | 2026/04
%20translateY(0)%20rotate(0deg);%20}%2050%25%20{%20transform:%20translateX(5px)%20translateY(-3px)%20rotate(10deg);%20}%20100%25%20{%20transform:%20translateX(0)%20translateY(0)%20rotate(0deg);%20}%20}%20@keyframes%20scaling%20{%200%25{%20transform:%20scale(.8);%20}%2050%25%20{%20transform:%20scale(1);%20}%20100%25%20{%20transform:%20scale(.8);%20}%20}%20.spin%20{%20transform-box:%20fill-box;%20transform-origin:%20center%20center;%20animation:%20spin%202s%20linear%20infinite%20alternate;%20}%20.scaling%20{%20transform-box:%20fill-box;%20transform-origin:%20center%20center;%20animation:%20scaling%203s%20linear%20infinite%20alternate;%20}%20%3c/style%3e%3c/defs%3e%3cg%20id='_圖層_1-2'%20data-name='圖層%201'%3e%3cg%3e%3cpath%20class='cls-2'%20d='M109.13,9.22c-3.38-6.39-12.97-8.36-18.6-3.82.96,8.6.13,17.39-2.4,25.66-3.15,10.28-8.83,19.56-14.22,28.86-.98,1.69-1.94,3.86-.83,5.46,1.19,1.73,3.79,1.42,5.82.88,8.68-2.32,17.86-5.96,22.38-13.73,2.25-3.88,3.1-8.39,3.8-12.82,1.64-10.29,2.73-20.67,4.05-30.51'/%3e%3cpath%20class='cls-1'%20d='M76.49,1.57c-15.28-3.92-32.67-.19-45.17,7.78-12.5,7.96-20.5,19.66-24.92,31.84C1.97,53.37.84,66.13.05,78.78c-.17,2.73-.06,5.92,2.71,7.54,3.11,1.82,7.64.47,10.55-1.56,2.91-2.02,5.21-4.71,8.74-5.98,2.76-1,5.92-1,8.95-.85,7.02.35,14.11,1.39,21.03.41,14.99-2.12,25.32-13,31.94-23.81,8.56-13.99,13.57-29.32,14.65-44.83.08-1.14.12-2.34-.54-3.36-1.03-1.57-3.39-2.22-5.57-2.64-6.19-1.2-12.72-1.29-16.02-2.14'/%3e%3cpath%20class='cls-1'%20d='M120.27,8.39c-3.92-.45-7.86-.65-11.81-.61-1.06.01-2.18.06-3.09.6-1.02.61-1.61,1.73-2.09,2.81-2.06,4.6-3.24,9.53-4.41,14.43-1.87,7.83-3.73,15.66-5.6,23.48-.32,1.35-.64,2.78-.22,4.11.99,3.11,5.42,3.64,8.31,2.13,2.89-1.52,4.89-4.3,7.51-6.25,4.72-3.51,11.39-4.27,15.16-8.79,2.76-3.31,3.47-8.15,6.78-10.9,3.4-2.83,9-2.96,11.11-6.85,2.27-4.17-1.58-9.34-6.02-11-4.44-1.67-9.17-2.42-15.64-3.17'/%3e%3cpath%20class='cls-3%20scaling'%20d='M47.26,38c-4.88,8.45-12.92,12.94-17.97,10.03-5.04-2.91-5.18-12.12-.3-20.57s12.92-12.94,17.97-10.03c5.04,2.91,5.18,12.12.3,20.57Z'/%3e%3cg%20class='spin'%3e%3cpath%20class='cls-4'%20d='M22.8,26.37c-.25,0-.49-.07-.71-.21-.61-.39-.78-1.21-.39-1.82,3.34-5.16,7.42-9.18,12.1-11.97.62-.37,1.43-.17,1.8.46.37.62.17,1.43-.46,1.8-4.34,2.58-8.12,6.33-11.24,11.14-.25.39-.67.6-1.1.6Z'/%3e%3cpath%20class='cls-4'%20d='M40.2,12c-.53,0-1.03-.32-1.23-.85-.26-.68.08-1.44.76-1.7,1.94-.74,3.94-1.31,5.95-1.69.72-.14,1.4.33,1.54,1.04.14.71-.33,1.4-1.04,1.54-1.85.35-3.71.88-5.5,1.57-.15.06-.31.09-.47.09Z'/%3e%3c/g%3e%3cpath%20class='cls-3%20scaling'%20style='animation-delay:%200.5s;'%20d='M64.1,20.38c-1.63,2.55-4.33,3.73-6.03,2.64-1.7-1.09-1.75-4.03-.12-6.58,1.63-2.55,4.33-3.73,6.03-2.64,1.7,1.09,1.75,4.03.12,6.58Z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)